Figure 5: In vivo antitumour activity evaluation of 2P. | Nature Communications

Figure 5: In vivo antitumour activity evaluation of 2P.

From: Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy

Figure 5

(a) In vivo tumour growth inhibition curves for PBS, Zn Control, oxaliplatin and 2P on the s.c. C26 tumour model. Oxaliplatin (dose, 5 mg kg−1) and 2P (dose, 2 mg kg−1) were administered on day 0, 2, 4 and 6. (b) Kaplan–Meier plots showing the percentage of animals remaining in the study with the s.c. C26 tumour model. (c) In vivo tumour growth inhibition curves for PBS, free oxaliplatin and 2P on the s.c. AsPC-1 tumour model. Oxaliplatin (dose, 5 mg kg−1) and 2P (dose, 2 mg kg−1) were administered on day 0, 4, 8, 12 and 16. Data are expressed as means±s.e.m. (n=5–8), *P<0.05, **P<0.01, ***P<0.001. (d) Photos of resected AsPC-1 tumours from various groups. From top to bottom: PBS, oxaliplatin and 2P.

Back to article page